IntronBio Develops New Salmonella-Specific Bacteriophage

Intronbio announced on the 28th that it has developed and secured a novel bacteriophage with specific antibacterial activity against Salmonella.

The New Drug Division is promoting technology development to continuously isolate and secure bacteriophages targeting harmful bacteria in both human and animal fields. They developed a new bacteriophage by applying a newly developed screening trait improvement technology.

Intronbio is supplying bacteriophage cocktail products that can proactively respond to harmful bacteria by developing bacteriophage-based antibiotic alternatives for animals. They are expanding the target scope to diversify their products.

Although bacteriophages are known to be widely present in the natural environment, industrial utilization requires meeting four factors: productivity, stability, efficacy, and safety. Developing an optimal bacteriophage cocktail requires significant effort, time, and cost.

By utilizing trait improvement technology related to bacteriophage screening, bacteriophages with specific traits can be isolated and secured more than twice as fast and accurately compared to previous methods.

Son Jisoo, head of the BD Division, stated, "The screening technology focused on storage stability, allowing us to select numerous bacteriophages with improved traits under selective pressure from temperature conditions."

He added, "We will diversify products capable of responding to widespread Salmonella as well as infections caused by Escherichia coli and Clostridium species."

Yoon Kyungwon, CEO of Intronbio, said, "We will seek changes to expand the market and explore cooperation plans," adding, "We plan to gradually strengthen the new product line."

This content was produced with the assistance of AI translation services.